These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 9371364)

  • 21. Susceptibilities of Neisseria gonorrhoeae isolates containing amino acid substitutions in GyrA, with or without substitutions in ParC, to newer fluoroquinolones and other antibiotics.
    Tanaka M; Nakayama H; Haraoka M; Saika T; Kobayashi I; Naito S
    Antimicrob Agents Chemother; 2000 Jan; 44(1):192-5. PubMed ID: 10602748
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Frequency of DNA gyrase and topoisomerase IV mutations and plasmid-mediated quinolone resistance genes among Escherichia coli and Klebsiella pneumoniae isolated from urinary tract infections in Azerbaijan, Iran.
    Azargun R; Soroush Barhaghi MH; Samadi Kafil H; Ahangar Oskouee M; Sadeghi V; Memar MY; Ghotaslou R
    J Glob Antimicrob Resist; 2019 Jun; 17():39-43. PubMed ID: 30445211
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dual-targeting properties of the 3-aminopyrrolidyl quinolones, DC-159a and sitafloxacin, against DNA gyrase and topoisomerase IV: contribution to reducing in vitro emergence of quinolone-resistant Streptococcus pneumoniae.
    Okumura R; Hirata T; Onodera Y; Hoshino K; Otani T; Yamamoto T
    J Antimicrob Chemother; 2008 Jul; 62(1):98-104. PubMed ID: 18390884
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization of quinolone resistance mechanisms in Enterobacteriaceae isolated from companion animals in Europe (ComPath II study).
    de Jong A; Muggeo A; El Garch F; Moyaert H; de Champs C; Guillard T
    Vet Microbiol; 2018 Mar; 216():159-167. PubMed ID: 29519511
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efflux and target mutations as quinolone resistance mechanisms in clinical isolates of Streptococcus pneumoniae.
    Broskey J; Coleman K; Gwynn MN; McCloskey L; Traini C; Voelker L; Warren R
    J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():95-9. PubMed ID: 10824039
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diverse phenotypic and genotypic characterization among clinical Klebsiella pneumoniae and Escherichia coli isolates carrying plasmid-mediated quinolone resistance determinants.
    Yang J; Luo Y; Cui S; Wang W; Han L
    Microb Drug Resist; 2011 Sep; 17(3):363-7. PubMed ID: 21563956
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bactericidal activity of the fluoroquinolone DU-6859a alone and in combination with other antimicrobial agents against multiresistant enterococci.
    Korten V; Erdem I; Murray BE
    Diagn Microbiol Infect Dis; 1996 Oct; 26(2):79-85. PubMed ID: 8985660
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibacterial activities and inhibitory effects of sitafloxacin (DU-6859a) and its optical isomers against type II topoisomerases.
    Akasaka T; Kurosaka S; Uchida Y; Tanaka M; Sato K; Hayakawa I
    Antimicrob Agents Chemother; 1998 May; 42(5):1284-7. PubMed ID: 9593169
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Determination of gyrA and parC mutations and prevalence of plasmid-mediated quinolone resistance genes in Escherichia coli and Klebsiella pneumoniae isolated from patients with urinary tract infection in Iran.
    Mirzaii M; Jamshidi S; Zamanzadeh M; Marashifard M; Malek Hosseini SAA; Haeili M; Jahanbin F; Mansouri F; Darban-Sarokhalil D; Khoramrooz SS
    J Glob Antimicrob Resist; 2018 Jun; 13():197-200. PubMed ID: 29747008
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Type II topoisomerase mutations in fluoroquinolone-resistant clinical strains of Pseudomonas aeruginosa isolated in 1998 and 1999: role of target enzyme in mechanism of fluoroquinolone resistance.
    Akasaka T; Tanaka M; Yamaguchi A; Sato K
    Antimicrob Agents Chemother; 2001 Aug; 45(8):2263-8. PubMed ID: 11451683
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antibacterial activity of the new quinolone CI-960 (PD 127391) against clinical isolates at a major tertiary care center in Saudi Arabia.
    Qadri SM; Abo-Askar H; Ueno Y
    Chemotherapy; 1992; 38(2):92-8. PubMed ID: 1317281
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus.
    Gootz TD; Zaniewski RP; Haskell SL; Kaczmarek FS; Maurice AE
    Antimicrob Agents Chemother; 1999 Aug; 43(8):1845-55. PubMed ID: 10428901
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In-vitro antimicrobial activity of HSR-903, a new fluoroquinolone, against clinical isolates of Neisseria gonorrhoeae with quinolone resistance-associated alterations in GyrA and ParC.
    Deguchi T; Yasuda M; Ishihara S; Takahashi Y; Okezaki E; Nagata O; Saito I; Kawada Y
    J Antimicrob Chemother; 1997 Sep; 40(3):437-9. PubMed ID: 9338500
    [TBL] [Abstract][Full Text] [Related]  

  • 34. gyrA mutations associated with fluoroquinolone resistance in eight species of Enterobacteriaceae.
    Weigel LM; Steward CD; Tenover FC
    Antimicrob Agents Chemother; 1998 Oct; 42(10):2661-7. PubMed ID: 9756773
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alteration in the GyrA subunit of DNA gyrase and the ParC subunit of DNA topoisomerase IV in quinolone-resistant clinical isolates of Staphylococcus epidermidis.
    Li Z; Deguchi T; Yasuda M; Kawamura T; Kanematsu E; Nishino Y; Ishihara S; Kawada Y
    Antimicrob Agents Chemother; 1998 Dec; 42(12):3293-5. PubMed ID: 9835531
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates.
    Smith HJ; Walters M; Hisanaga T; Zhanel GG; Hoban DJ
    Antimicrob Agents Chemother; 2004 Oct; 48(10):3954-8. PubMed ID: 15388458
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ParC and GyrA may be interchangeable initial targets of some fluoroquinolones in Streptococcus pneumoniae.
    Varon E; Janoir C; Kitzis MD; Gutmann L
    Antimicrob Agents Chemother; 1999 Feb; 43(2):302-6. PubMed ID: 9925523
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alterations in the GyrA subunit of DNA gyrase and the ParC subunit of DNA topoisomerase IV associated with quinolone resistance in Enterococcus faecalis.
    Kanematsu E; Deguchi T; Yasuda M; Kawamura T; Nishino Y; Kawada Y
    Antimicrob Agents Chemother; 1998 Feb; 42(2):433-5. PubMed ID: 9527801
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel Ser79Leu and Ser81Ile substitutions in the quinolone resistance-determining regions of ParC topoisomerase IV and GyrA DNA gyrase subunits from recent fluoroquinolone-resistant Streptococcus pneumoniae clinical isolates.
    Korzheva N; Davies TA; Goldschmidt R
    Antimicrob Agents Chemother; 2005 Jun; 49(6):2479-86. PubMed ID: 15917550
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Uncommon occurrence of fluoroquinolone resistance-associated alterations in GyrA and ParC in clinical strains of Chlamydia trachomatis.
    Yokoi S; Yasuda M; Ito S; Takahashi Y; Ishihara S; Deguchi T; Maeda S; Kubota Y; Tamaki M; Fukushi H
    J Infect Chemother; 2004 Oct; 10(5):262-7. PubMed ID: 16163459
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.